<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112077">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644253</url>
  </required_header>
  <id_info>
    <org_study_id>16009</org_study_id>
    <nct_id>NCT01644253</nct_id>
  </id_info>
  <brief_title>Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU 016 in Combination With Rituximab, in Combination With Obinutuzumab, in Combination With Rituximab and Idelalisib, or in Combination With Ibrutinib in Patients With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptevo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptevo Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of TRU-016 when when
      administered in combination with rituximab or obinutuzumab, in combination with idelalisib
      and rituximab, or in combination with ibrutinib in patients with chronic lymphocytic
      leukemia (CLL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>any time point during the study up to 18 months</time_frame>
    <description>ORR by the 2008 International Workshop on CLL (IWCLL) criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cysteine 481 mutant clone</measure>
    <time_frame>any time point during the study</time_frame>
    <description>The primary endpoint for Cohort 7 is the elimination of the cysteine 481 mutant clone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>any time point during the study up to 18 months</time_frame>
    <description>The incidence and severity of adverse events, and changes from baseline in laboratory parameters, vital signs, and physical examination will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>any time point during the study up to 18 months</time_frame>
    <description>ORR by 1996 NCI Working Group Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>any time point during the study up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>any time point during the study up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>any time point during the study up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of disease-related symptoms</measure>
    <time_frame>Any time point during the study up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Previously Untreated CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg TRU-016 + Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Relapsed CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg TRU-016 + Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Previously Untreated CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg TRU-016 + Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Previously Untreated CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg TRU-016 20 + Obinutuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 - Relapse CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg TRU-016 + idelalisib + rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 - With CLL on ibrutinib with no complete response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg TRU-016 + ibrutinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 - With CLL on ibrutinib with stable disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg TRU-016 + ibrutinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20 mg/kg TRU-016 + Rituximab</intervention_name>
    <description>TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses
Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses</description>
    <arm_group_label>Cohort 1 - Previously Untreated CLL</arm_group_label>
    <arm_group_label>Cohort 2 - Relapsed CLL</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 mg/kg TRU-016 + Rituximab</intervention_name>
    <description>TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses
Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule</description>
    <arm_group_label>Cohort 3 - Previously Untreated CLL</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TRU-016 20 mg/kg + Obinutuzumab</intervention_name>
    <description>TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months
Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months</description>
    <arm_group_label>Cohort 4 - Previously Untreated CLL</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TRU-016 6-20 mg/kg + idelalisib + rituximab</intervention_name>
    <description>TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.</description>
    <arm_group_label>Cohort 5 - Relapse CLL</arm_group_label>
    <other_name>Zydelig, Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TRU-016 10-20 mg/kg + ibrutinib</intervention_name>
    <description>TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.</description>
    <arm_group_label>Cohort 6 - With CLL on ibrutinib with no complete response</arm_group_label>
    <arm_group_label>Cohort 7 - With CLL on ibrutinib with stable disease</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CLL by 2008 IWCLL criteria and with Rai stage intermediate or high risk
             CLL

          -  No prior therapy for CLL for Cohorts 1, 3 and 4. For Cohort 2, 1-3 prior treatments.
             For Cohort 5, patients must have failed to respond or relapsed after 1 or more
             treatment regimens. For Cohort 6, patients who have been receiving ibrutinib for at
             least 12 months, have not had a CR, and in whom no cysteine 481 mutation is detected.
             For Cohort 7, patients who are receiving ibrutinib with stable disease and now have
             the cysteine 481 mutant clone present at levels of &gt;1%.

          -  At least one of the following criteria for active disease requiring treatment:
             progressive splenomegaly and/or lymphadenopathy; anemia or thrombocytopenia due to
             bone marrow involvement; or progressive lymphocytosis with an increase of &gt;50% over a
             2-month period or an unanticipated doubling time of less than 6 months

          -  For Cohorts 1, 3 and 4, contraindication to chemotherapy as first-line therapy due to
             patient age, comorbidity or patient preference

          -  Age &gt;/= to 18 years

          -  ECOG performance status of &lt;/= 2

          -  Life expectancy &gt; 6 months in opinion of Investigator

          -  Serum creatinine, total bilirubin, ALT/SGPT &lt;/= 2.0 x upper limit of normal

          -  ANC &gt;/= 800/mm3

          -  Platelets &gt;/= 30,000/mm3

        Exclusion Criteria:

          -  For Cohorts 1, 3 and 4 only: Has received treatment with rituximab, alemtuzumab,
             ofatumumab or any other chemotherapeutic agent for CLL

          -  Has received an investigational therapy within 30 days of first dose of study drug

          -  Previous or concurrent additional malignancy

          -  Clinically significant pulmonary dysfunction, active infection, prior allogeneic bone
             marrow transplant, active autoimmune disease

          -  Positive serology for HIV or hepatitis C

          -  Hepatitis B surface antigen or hepatitis B core antibody positive

          -  Pregnant or breastfeeding

          -  Known current drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott C. Stromatt, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Aptevo Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Zovath</last_name>
    <phone>512 649 6619</phone>
    <email>jennifer.zovath@inventivhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding sites for this trial call (919) 465-4648</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>For additional information regarding sites for this trial call (919) 465-4648</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Zovath</last_name>
      <phone>512-649-6619</phone>
      <email>jennifer.zovath@inventivhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Whitlow</last_name>
      <phone>614-688-9495</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>For additional information regarding sites for this trial call (919) 465-4648</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute,1221 Madison St.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donielle O'Connor</last_name>
      <phone>206-386-2444</phone>
      <email>donielle.o'connor@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Zovath</last_name>
      <phone>614-688-9495</phone>
      <email>jennifer.zovath@inventivhealth.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>July 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>previously untreated chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Idelalisib</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
